Stem Cell-Like Gene Expression in Ovarian Cancer Predicts Type II Subtype and Prognosis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Schwede, Matthew ^a   Spentzos, Dimitrios ^c   Bentink, Stefan ^a,d   Hofmann, Oliver ^b   Haibe Kains, Benjamin ^a,e   Harrington, David ^a,b   Quackenbush, John ^a,b   Culhane, Aedín C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Exosome Diagnostics GmbH   (Germany)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT STEM CELL; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; EMBRYONIC STEM CELL; GENE EXPRESSION; HISTOPATHOLOGY; OVARY CANCER; RISK FACTOR; STATISTICAL MODEL; STEM CELL;

ADULT; AGED; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, BASAL CELL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84874854042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057799     Document Type: Article

References (68)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310.
3. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, et al. (2011) Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10: 325-335.
4. Hu L, McArthur C, Jaffe RB, (2010) Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102: 1276-1283.
5. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR, (2011) Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 16: 368-392.
6. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
7. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
8. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, et al. (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105: 1680-1685.
9. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, et al. (2009) High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 69: 663-671.
10. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
11. Cancer Genome Atlas Research Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
12. Kurman RJ, Shih Ie M, (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
13. Karst AM, Drapkin R, (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010: 932371.
14. Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, et al. (2009) Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33: 1220-1224.
15. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
17. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175-e175.
18. Sandberg R, Larsson O, (2007) Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics 8: 48.
19. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525.
20. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11: 321-333.
21. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, et al. (2008) Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 14: 4067-4078.
22. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: e24.
23. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
24. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
25. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
26. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, et al. (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104: 6740-6745.
27. Millenaar FF, Okyere J, May ST, van Zanten M, Voesenek LA, et al. (2006) How to decide? Different methods of calculating gene expression from short oligonucleotide array data will give different results. BMC Bioinformatics 7: 137.
28. Li C, Wong WH, (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36.
29. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165.
30. Foulkes WD, Smith IE, Reis-Filho JS, (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
31. Carey L, Winer E, Viale G, Cameron D, Gianni L, (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692.
32. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
33. von Heydebreck A, Huber W, Poustka A, Vingron M, (2001) Identifying splits with clear separation: a new class discovery method for gene expression data. Bioinformatics 17 (Suppl 1): S107-114.
34. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, et al. (2012) Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One 7: e30269.
35. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, et al. (2009) GeneSigDB-a curated database of gene expression signatures. Nucleic Acids Res.
36. Jiang Z, Gentleman R, (2007) Extensions to gene set enrichment. Bioinformatics 23: 306-313.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
38. Dudoit S, Fridlyand J, Speed TP, (2002) Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data. Journal of the American Statistical Association 97: 77-87.
39. Fraley CaR, Adrian E, (2002) Model-Based Clustering, Discriminant Analysis, and Density Estimation. Journal of the American Statistical Association 97: 611-631.
40. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, et al. (2010) Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 11: 733-739.
41. Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, et al. (2007) A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 25: 961-973.
42. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
43. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
44. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, et al. (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26: 2126-2132.
45. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
46. Hommel G, (1988) A Stagewise Rejective Multiple Test Procedure Based on a Modified Bonferroni Test. Biometrika 75: 383-386.
47. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, et al. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6: 276.
48. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, et al. (2008) Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 99: 324-332.
49. Okada A, Ohta Y, Brody SL, Watanabe H, Krust A, et al. (2004) Role of foxj1 and estrogen receptor alpha in ciliated epithelial cell differentiation of the neonatal oviduct. J Mol Endocrinol 32: 615-625.
50. Levanon K, Crum C, Drapkin R, (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293.
51. Burgos-Ojeda D, Rueda BR, Buckanovich RJ, (2012) Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 322: 1-7.
52. Wang Y, Sacchetti A, van Dijk MR, van der Zee M, van der Horst PH, et al. (2012) Identification of quiescent, stem-like cells in the distal female reproductive tract. PLoS One 7: e40691.
53. Zhang H, Zheng W, Shen Y, Adhikari D, Ueno H, et al. (2012) Experimental evidence showing that no mitotically active female germline progenitors exist in postnatal mouse ovaries. Proc Natl Acad Sci U S A 109: 12580-12585.
54. Shats I, Gatza ML, Chang JT, Mori S, Wang J, et al. (2011) Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 71: 1772-1780.
55. Dehari R, Kurman RJ, Logani S, Shih Ie M, (2007) The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 31: 1007-1012.
56. Tang Y, Shu G, Yuan X, Jing N, Song J, (2011) FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res 21: 316-326.
57. Song Y, Washington MK, Crawford HC, (2010) Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70: 2115-2125.
58. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, et al. (2008) Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122: 91-99.
59. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F, (2009) An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 8: 1893-1905.
60. Sherman MH, Bassing CH, Teitell MA (2011) Regulation of cell differentiation by the DNA damage response. Trends Cell Biol.
61. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ, (2010) Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol 63: 879-883.
62. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, et al. (2010) Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology 77: 283-288.
63. Bowtell DD, (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
64. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
65. Mizuno H, Spike BT, Wahl GM, Levine AJ, (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A 107: 22745-22750.
66. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
67. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, et al. (2010) Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 16: 4702-4710.
68. Banerjee S, Kaye SB, Ashworth A, (2010) Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 7: 508-519.